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OBJECTIVES We examined the relationship between the angiotensinogen (AGT) gene M235T polymor-
phism, the variant promoter of the AGT gene A(-6)G and the angiotensin-converting
enzyme (ACE) gene insertion/deletion (I/D) polymorphism and coronary heart disease
(CHD) in native Gran Canaria Island habitants, who have the highest rates of CHD in
Spain.
BACKGROUND Some studies subject that the ACE (I/D) polymorphism could be associated with CHD,
while AGT (M235T) has been related to essential hypertension.
METHODS We studied 304 subjects with angiographic evidence of coronary artery disease and a clinical
diagnosis of myocardial infarction or unstable angina and 315 age- and gender-matched
controls. Blood was drawn and DNA extracted. Angiotensin-converting enzyme (I/D) gene
polymorphism was analyzed by polymerase chain reaction (PCR) and AGT gene polymor-
phisms by restriction fragment length polymorphism-PCR and mutagenically-separated
PCR.
RESULTS The ACE (I/D) polymorphism showed no association with CHD, whereas the frequency
distribution of AGT (M235T) genotypes among patients and controls (235T: 29.1% and
19.0%; M235T: 48.5% and 50.2%; M235: 22.4% and 30.8%, respectively) was statistically
different (p 5 0.005) and not related to the presence of essential hypertension. Similar results
were observed with the AGT A(-6)G polymorphism. In multiple logistic regression analysis,
CHD odds ratio associated with 235T and M235 homozygotes were 1.7 (1.1 to 2.6) and 0.54
(0.36 to 0.82), respectively.
CONCLUSIONS This study shows that genetic variation of the AGT (M235T), but not the ACE (I/D),
genotypes contributes to the presence of CHD independently of blood pressure profile in a
subset of the Spanish population with a high prevalence of cardiovascular disease. (J Am Coll
Cardiol 2001;37:1536–42) © 2001 by the American College of Cardiology
The World Health Organization estimates that six million
people will die from cardiovascular diseases (CVD) in
industrialized countries annually (1). While the role of risk
factors (smoking, high blood pressure [BP] and cholesterol)
for coronary heart disease (CHD) is acknowledged (2),
emerging evidence suggests a contribution of genetic fac-
tors. Among various candidates, the genes coding for the
proteins of the renin-angiotensin system may contribute to
the evolution of CHD (3).
Identification of a polymorphism in the gene coding for
the angiotensin-converting enzyme (ACE) gene involving
an insertion (I) or deletion (D) on intron 16 (4) has been
followed with considerable interest in genetic association
studies. The D allele was associated with higher plasma
levels of ACE (4). A retrospective multicenter case-control
study showed that the frequency of the DD genotype was
higher in subjects with myocardial infarction (MI) recruited
between three and nine months after the event (5). Al-
though subsequent studies did not confirm this finding, a
meta-analysis (6) of the literature suggested an association
between the D allele and ischemic heart disease.
The angiotensinogen (AGT) gene has been associated
with heart disease progression. A polymorphism in exon 2
of the AGT gene, a threonine to methionine substitution at
position 235 (M235T), has been associated with higher BP
and higher AGT levels in populations of Caucasian (7,8)
and African-Caribbean ancestry (9), as well as the syndrome
of preeclampsia (10). Further investigation of the associa-
tion of 235T homozygosity showed a link with increased
risk of CHD (11). A molecular variant in the proximal
promoter of the AGT gene, an adenine instead of a
guanine, six nucleotides upstream from the site of transcrip-
tion initiation, A(-6)G, has been reported. Studies of
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binding between AGT promoter region oligonucleotides
and nuclear proteins strongly suggest that substitution at
nucleotide -6 affects specific interactions between at least
one transacting nuclear factor and the promoter of AGT
(12). Since A(-6)G is in very tight linkage disequilibrium
with M235T, the abnormal manifestations associated with
AGT (M235T) polymorphism could simply reflect the
modifications in the promoter activity induced by nucleotide
substitution at the -6 position. These observations provide a
biological insight on possible mechanisms for a genetic
predisposition to essential hypertension.
The Prospective Cardiac Gene (PROCAGENE) study is
a large case-control study designed to examine the relation-
ship between CVD risk factors, genetic markers in the
renin-angiotensin system and the presence of CHD in
individuals residing in Gran Canaria Island, Spain.
METHODS
Study population. The PROCAGENE study included
619 randomly selected persons (469 men and 150 women)
aged 25 to 79 years, identified prospectively in participating
centers in Gran Canaria Island (Canary Islands, Spain)
between January 1996 and December 1998. All subjects
completed the established protocol study. A case was
defined as an individual of Canarian/Spanish ancestry ad-
mitted to any hospital in Gran Canaria with a diagnosis of
MI or unstable angina and documented evidence of coro-
nary artery disease by angiography. All consecutive incident
cases admitted to the coronary unit were studied within the
study period to minimize selection bias. Age and gender-
matched controls were selected from the Gran Canaria
population (total population 713,768). Controls were ran-
domly ascertained by a two-stage stratified selection process.
Cities in Gran Canaria were randomly selected according to
their population size (,5,000; 5,000 to 19,999; 20,000 to
49,999; 50,000 to 99,999; .99,999 habitants), and poten-
tial controls were selected from each of the cities. These
underwent diagnostic tests to exclude CVD.
Canarian/Spanish ancestry was defined as being born in
the Canaries to Canarian parents or subjects of Spanish
ancestry residing in the island for more than 10 years. The
Canarian population is considered to be relatively homoge-
neous since it was in isolation until the seventies. Urban
dwelling was defined as living in cities with more than
100,000 habitants. All participants were interviewed by a
trained nurse who followed a standardized questionnaire to
collect demographic, lifestyle, anthropometry and medica-
tion use. Smoking status was classified as current smoker or
nonsmoker. Obesity was defined as a body mass index
(BMI) $26 kg/m2, a value that reflects the Canarian
population BMI distribution.
Subjects underwent three supine BP measurements ac-
cording to the criteria established by the American Heart
Association using an Omron Hem 705CP semiautomatic
device calibrated in accordance with the protocol described
by the British Society of Hypertension (13). Blood pressure
was measured in the right arm after subjects had voided,
abstained from smoking for at least 15 min and rested for
5 min in the decubitus position. Triplicate measurements
spaced 30 s apart were taken on the same arm by a trained
nurse. Fasting blood and urine samples were obtained for
genotyping, biochemistry, urinary creatinine and albumin
excretion determinations.
The study was approved by our institutional research
ethics committee, and informed consent was obtained from
all participants.
Laboratory methods. BIOCHEMICAL MEASUREMENTS.
Plasma glucose, serum creatinine, total cholesterol, high-
density lipoprotein cholesterol and triglycerides were mea-
sured by enzymatic-colorimetric methods. Low-density li-
poprotein cholesterol was calculated according to the
Friedewald formula when triglyceride levels were
#400 mg/dl. Lipoprotein (a) (Lp [a]) was analyzed with an
immunoturbidimetric method (Boehringer-Mannheim,
Germany), and plasma homocysteine was measured by the
Fluorescence Polarization Immunoassay (Abbott, Diagnos-
tic Division, Chicago, Illinois), with an intraassay coefficient
of variation of 1.9%. Microalbuminuria was measured by an
immunoturbidimetric assay (Boehringer-Mannheim, Ger-
many).
GENOTYPING OF THE ACE (I/D) AND AGT (M235T) AND A(-6)G
POLYMORPHISMS. DNA was extracted from leukocytes by
standard procedures (14). The ACE (I/D) genotypes were
determined according to previously described conditions
(15) with minor modifications. The reaction was performed
with 10 pmol of primers 59 CTG GAG ACC ACT CCC
ATC CTT TCT 39 and 59 GAT GTG GCC ATC ACA
TTC GTC AGA T 39. Because previous reports suggested
that the D allele is preferentially amplified in heterozygotes
(16), each sample expressing the ACE-DD genotype was
subjected to a second independent polymerase chain reac-
tion (PCR) amplification with insertion-specific primers
(17): hace5a, 59 TGG GAC CAC AGC GCC CGC CAC
TAC 39 and hace5c, 59 TCG CCA GCC CTC CCA
TGC CCA TAA 39. Data were corrected for this misclas-
sification. We used an amplification protocol described
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previously (18), I/D and I/I samples as amplification con-
trols.
The AGT (M235T) polymorphism was typed by the
mismatch method previously described (8). Primers used
were: AGT1, 59 GAT GCG CAC AAG GTC CTG TC
39 and AGT2, 59 CAG GGT GCT GTC CAC ACT
GGC TCG C 39.
The AGT A(-6)G polymorphism was determined by
mutagenically separated PCR as described by Morgan et al.
(19) with minor modifications. In brief, three primers were
used: 1) AGT-6MS59: 59 GTG TCG CTT CTG GCA
TCT GTC CTT CTG G 39 a common forward primer; 2)
AGT-6MS39S: 59 TAC CCA GAA CAA CGG CAG
CTT CTT CCA CT 39 for the detection of allele A(-6);
and 3) AGT-6MS39L: 59 CCG GTT ACC TTC TGC
TGT AGA GCC CAG AAC AAC GGC AGC TTC
TTC CAT C 39 for the detection of allele (-6)G.
Two pmol of AGT-6MS59, 4 pmol of AGT-6MS39S
and 8 pmol of AGT-6MS39L were used. Since a limited
amount of DNA was obtained, we failed to analyze four
subjects for ACE (I/D), five for AGT (M235T) and five for
AGT A(-6)G polymorphisms.
Statistical analyses. The SPSS statistical software package
(SPSS 8.0, Chicago, Illinois) was used for analysis of the
data. A p value ,0.05 was considered statistically signifi-
cant. All continuous variables are reported as mean 6 SD.
The unpaired t test was used for comparison of group’s
means. Frequencies of gene variants with coronary risk
factors were evaluated by chi-square analysis. The
Kolmogorov-Smirnov test was employed for estimation of
the normal distribution of the variables. Mantel-Haenszel
chi-square and odds ratios (OR) with 95% confidence
intervals (CI) analysis were carried out to estimate the risk
of CHD associated with continuous variables (age ,50 or
$50 years old; BMI ,26 or $26; alcohol consumption
,30 or $30 g/day; systolic BP ,140 or $140 mm Hg;
diastolic BP ,90 or $90 mm Hg; cholesterol #200 or
.200 mg/dl; high-density lipoprotein cholesterol #65 or
.65 mg/dl; low-density lipoprotein cholesterol #160 or
.160 mg/dl; triglycerides #150 or .150 mg/dl; total
cholesterol/high-density lipoprotein cholesterol ratio #5 or
.5; Lp (a) #30 or .30 mg/dl; glucemia #126 or
.126 mg/dl; creatinine ,1 or $1 mg/dl; homocysteine
#15 or .15 mmol/L; microalbuminuria ,30 or $30 mg/g
of creatinine) and the categorical variables: gender, urban/
rural life, smoking, sedentary habit, diabetes and hyperten-
sion.
The Hardy-Weinberg equilibrium for the frequencies of
the ACE and AGT genotypes was tested by chi-square
analysis. Odds ratios and 95% CI were calculated to
estimate the relative risks of CHD associated with ACE
(I/D), AGT (M235T) and AGT A(-6)G polymorphisms.
To assess the independent variable predictor ability for
CHD, we performed multiple logistic regression analysis
with the backward stepwise method. The contribution of
analyzed genotypes and reported CHD risk factors in
predicting the dependent variable (coronary event) when all
other independent variables were allowed for was expressed
as an OR (eb) with 95% CIs (eb 6 1.96 3 SE). The model
included the classical risk factors that attained statistical
significance in the univariate analysis (urban/rural dwelling,
smoking, alcohol intake, diabetes, hypertension, glucemia,
Lp (a), high-density lipoprotein cholesterol, total
cholesterol/high-density lipoprotein cholesterol ratio) and
ACE and AGT genotypes. All the variables were trans-
formed in dummy variables, taking the value 1 for the
presence of the characteristic and 0 for its absence. Taking
a cut-off point of 50%, the established model classified
correctly 71% of individuals.
RESULTS
Study patients, lifestyle and cardiovascular risk factors.
Three hundred and four cases (mean age 56 6 10 years,
22% women) and 315 randomly selected age- and gender-
matched community controls (mean age 54 6 10 years, 26%
women) were included in the study. Table 1 shows the main
characteristics of our case and control groups. Hypertension
(chi-square 5 13.84; p , 0.001), diabetes (chi-square 5
41.86; p , 0.001), smoking (chi-square 5 33.67; p ,
0.001) and urban habitat (chi-square 5 7.13; p 5 0.008)
were significantly higher in the group of patients compared
with the group of controls. The control group presented
higher levels of high-density lipoprotein cholesterol (p ,
0.001).
Cases and controls did not differ significantly with regard
to BMI, systolic BP and microalbuminuria. However,
diastolic BP values, total cholesterol, triglycerides and low-
density lipoprotein cholesterol were lower in cases than they
were in controls, most likely due to a higher frequency of
treatment with antihypertensive and lipid-lowering agents
among cases. Patients with a diagnosis of coronary artery
disease showed a significant increase in total cholesterol/
high-density lipoprotein cholesterol ratio and plasma Lp (a)
(t 5 7.68 and t 5 3.63, respectively, both p , 0.001).
Paradoxically, plasma homocysteine levels were higher in
controls compared with cases, albeit within normal range for
both groups.
Table 1. Main Clinical Characteristics of Cases and Controls
Cases
(n 5 304)
Controls
(n 5 315)
p
Value
Diastolic BP (mm Hg) 76 6 13 84 6 12 ,0.001
Alcohol intake (g/day) 16 6 27 11 6 19 0.012
HDL-cholesterol (mg/dl) 35 6 9 50 6 12 ,0.001
Total chol./HDL-chol. ratio 5.9 6 1.7 4.9 6 1.3 ,0.001
Homocysteine (mmol/L) 14.5 6 5.2 15.7 6 7.3 0.029
Lp (a) (mg/dl) 54 6 68 37 6 43 ,0.001
Fasting blood glucose (mg/dl) 112 6 50 105 6 28 0.041
BP 5 blood pressure; chol. 5 cholesterol; HDL 5 high-density lipoprotein; Lp(a) 5
lipoprotein (a).
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Distribution of ACE and AGT genotypes among cases
and controls. For each polymorphism ACE (I/D), AGT
(M235T) and AGT A(-6)G, we confirmed that the geno-
type proportions fit the Hardy-Weinberg equilibrium esti-
mated by chi-square test. The ACE-DD genotype fre-
quency was higher in our population when compared with
those described for other Caucasian populations (17,20–
23), probably because of ethnicity, although this genotype
was at nonsignificant increased frequency among CHD
patients. Examination of this distribution showed a signif-
icant difference in the AGT (M235T) polymorphism (chi-
square 5 10.59; p 5 0.005) and A(-6)G (chi-square 5 8.09;
p 5 0.01) among patients and controls (Table 2). The
frequency of 235T and A(-6) homozygotes was higher
(chi-square 5 8.50; p 5 0.004 and chi-square 5 6.78; p 5
0.009) in cases than it was in controls. The allele frequencies
were p (T) 5 0.53 and 0.44, p (A) 5 0.54 and 0.46 for
patients and controls, respectively.
The molecular variant in the proximal promoter of the
AGT gene, A(-6)G, was in tight linkage disequilibrium
with M235T, consistent with previously reported results
(12). G and A alleles were closely associated with M and T
alleles, respectively, as revealed by the haplotype frequencies
in case (G-M: 0.449, G-T: 0.010, A-T: 0.522 and A-M:
0.019) and control (G-M: 0.533, G-T: 0.005, A-T: 0.438
and A-M: 0.024) populations.
The OR for CHD among individuals with the analyzed
genotypes is depicted in Figure 1. The analyses did not
show a statistically significant difference for the ACE (I/D)
polymorphism between cases and controls. The CHD OR
associated with 235T homozygosity was 1.74 (CI: 1.20 to
2.54; p 5 0.004) and 1.63 (CI: 1.22 to 2.35; p 5 0.009) for
A(-6) homozygotes. The ORs for M235 and (-6)G ho-
mozygosity were 0.64 (CI: 0.45 to 0.93; p 5 0.01) and 0.69
(CI: 0.48 to 1.00; p 5 0.05), respectively. No differences
between patients and controls were observed in heterozy-
gote subjects (Fig. 1A). Finally, we analyzed the association
of ACE (I/D) and AGT (M235T) as well as ACE (I/D)
and AGT A(-6)G genotype combinations with CHD risk
(Fig. 1B). The CHD OR associated with AGT-235T and
with AGT A(-6) was 2.06 (CI: 1.20 to 3.51; p , 0.001) and
1.8 (CI: 1.07 to 3.02; p 5 0.02), respectively, among
subjects with ACE-I/D.
Since AGT (M235T) has been associated with arterial
hypertension in previous analyses, we studied the distribu-
tion of this gene polymorphism in the hypertensive and
normotensive groups of our population. As shown in Table
3, no statistically significant differences in the genotype
distribution between hypertensive subjects and normoten-
sive subjects were observed, both in case and control groups
(b 5 0.004). Thus, genotype distribution differences be-
tween cases and controls for hypertensive and normotensive
groups were the same as that previously determined for the
total population.
On multiple logistic regression analysis and in agreement
with the previous data, we found an association between
CHD and the homozygotes for AGT (M235T) polymor-
phism (Table 4). On the other hand, we determined an
OR 5 1.5 (CI: 0.98 to 2.3; p 5 0.06) for the AGT A(-6)
homozygote and OR 5 0.6 (CI: 0.39 to 0.91; p 5 0.02) for
the AGT (-6)G homozygote. Of interest is that analysis of
genotype combinations revealed an enhanced protection for
CHD in those subjects with AGT-M235 1 ACE-II
(OR 5 0.24; CI: 0.07 to 0.77; p 5 0.02) or AGT (-6)G 1
ACE-II (OR 5 0.24; CI: 0.07 to 0.81; p 5 0.02).
DISCUSSION
The principles of genetic approaches to complex diseases
have been reviewed (24). The field is complicated by issues
related to sample size, definition of ethnicity, publication
bias toward positive results and inaccurate definition of
disease phenotypes (6,25). The PROCAGENE study is
based on clear characterization of the phenotype of ischemic
heart disease in an isolated Spanish subpopulation with the
highest rate of CHD (26) in Spain. The study design
minimized potential confounding by differences in ethnicity
by limiting, by design, the inclusion of individuals from
other geographical regions.
ACE (I/D) polymorphism in CHD. In contrast with
other studies (5,6,27,28), our results show no evidence of an
association between ACE polymorphisms and CHD in the
population of Gran Canaria Island. Consistent with previ-
ously reported data, we found a trend towards a decrease in
CHD of those subjects with ACE-II (OR 5 0.70), al-
though this did not reach statistical difference, probably
reflecting a lower frequency of this genotype (17). Cambien
et al. (5) first described an association between the DD
genotype of the ACE gene polymorphism and MI. Other
studies found an association with CHD (29), MI (30),
hypertrophic cardiomyopathy (31), coronary artery resteno-
sis (32), dilated cardiomyopathy (33) and parental history of
MI (27). However, conclusions derived from these studies
remain controversial due to the lack of association between
Table 2. ACE and AGT Genotype Distribution in Cases
and Controls
Gene
Polymorphism Genotype
Cases
n (%)
Controls
n (%)
Chi-Square
df
p
Value
ACE-I/D DD 128 (42.7) 138 (43.8)
ID 140 (46.7) 131 (41.6)
II 32 (10.6) 46 (14.6)
Total 300 (100) 315 (100) 2.82 0.244
AGT-M235T TT 87 (29.1) 60 (19.0)
MT 145 (48.5) 158 (50.2)
MM 67 (22.4) 97 (30.8)
Total 299 (100) 315 (100) 10.59 0.005
AGT-A(26)G AA 90 (29.9) 65 (20.8)
AG 146 (48.5) 159 (50.8)
GG 65 (21.6) 89 (28.4)
Total 301 (100) 313 (100) 8.09 0.017
ACE-DD is expressed as DD; ACE-ID as ID and ACE-II as II. AGT-235T,
AGT-M235T and AGT-M235 were expressed as TT, MT and MM, respectively.
AGT A(26), AGT A(26)G and AGT (26)G were expressed as AA, AG and GG,
respectively.
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DD genotype and CHD in other reports (6,17,34). These
findings stress the necessity of considering ethnic factors in
the assessment of genetic risk identifiers.
AGT polymorphisms in CHD. Angiotensinogen-235T
was present in 19% of our control population compared with
15% for individuals in Western populations (7). Our results
provide strong evidence of an association between the AGT
gene and the risk for CHD. In keeping with other studies
(11), homozygosity for 235T was associated with increased
risk for CHD (unadjusted OR 5 1.74), while the M235
homozygote seems to be associated with a decreased risk for
CHD (OR 5 0.64). The OR of 235T homozygosity for
CHD was similar in the multivariate analyses without BP or
other variables overlapping its predictor information. Sim-
ilar results were found with the molecular variant localized
in the proximal promoter of the AGT. It has been suggested
in previous studies that the T allele might be associated with
the cardiovascular complications of hypertension.
Angiotensinogen-235T homozygosity was associated with
essential hypertension in Japanese populations (35) and with
controversy in white Europeans (7,8). Although the associ-
ation studies suggest a role of the AGT gene, the linkage of
the AGT gene and essential hypertension first reported by
Jeunemaitre et al. (7) has not been replicated in others
Figure 1. Estimates of risk of coronary heart disease associated with polymorphism in the genes coding for angiotensin-converting enzyme (ACE) and
angiotensinogen (AGT). (A) Odds ratio (OR) according to genotypes for the ACE (I/D), AGT (M235T) or AGT A(-6)G polymorphisms. (B) Analysis
of the risk associated with a determined genotype combination of ACE (I/D) and AGT (M235T) or AGT A(-6)G polymorphisms in relation to the
remaining possible combinations. Genotype abbreviations are the same as those shown in Table 2. *p , 0.05.
Table 3. AGT (M235T) Genotype Distribution in Hypertensives and Normotensives
Genotypes
Cases n (%) Controls n (%)
Hypertensives Normotensives Total Hypertensives Normotensives Total
Chi-Square 5 0.33; p 5 0.85 Chi-Square 5 0.47; p 5 0.79
AGT-235T 42 (29.4) 45 (28.8) 87 (29.1) 21 (19.8) 39 (18.7) 60 (19.0)
AGT-M235T 71 (49.7) 74 (47.4) 145 (48.5) 55 (51.9) 103 (49.3) 158 (50.2)
AGT-M235 30 (21.0) 37 (23.7) 67 (22.4) 30 (28.3) 67 (32.1) 97 (30.8)
Totals: 143 156 299 106 209 315
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studies (36,37). Here, we described that 235T homozygos-
ity was a risk factor for CHD independent of BP in a
Caucasian population. Although it has been demonstrated
by increased AGT synthesis (12) and angiotensin II pro-
duction in AGT-235T homozygotes, mechanisms by which
AGT-235T genotype could be contributing to the devel-
opment of CHD is unknown, primarily because of pleio-
tropic actions of angiotensin II. Other factors involved in
artery wall injury should be considered. A more complex
than originally envisioned stepwise enzymatic processing
assumed to sequentially convert AGT into angiotensin II
(38) could explain why AGT (M235T), but not ACE
(I/D), polymorphism was associated with CHD.
Genotype combinations of ACE (I/D) and AGT poly-
morphisms in CHD. Univariate analysis showed that the
combination of the AGT-235T and ACE-I/D genotypes
further enhanced the risk of CHD compared with separate
association analysis of each gene. This increased risk for
CHD among individuals with AGT-235T 1 ACE-I/D has
not been documented previously. Similar results were ob-
served in the AGT A(-6) 1 ACE-I/D combination. The
precise mechanism by which these genotype-related effects
could be additive in the risk of CHD is unclear. One
interpretation is that the ACE gene may confer suscepti-
bility to CVD via a system unrelated to angiotensin II.
Alternatively, the ACE (I/D) polymorphism may reflect a
marker for a functional gene variant that controls ACE
mechanisms. It must be considered that the contribution of
the ACE gene is relatively small given the fact that CHD is
multifactorial in its etiology and influenced by environmen-
tal factors.
We are not able to discard an interaction of ACE (I/D)
gene polymorphism with other genes in the RAS system not
investigated in this study. In this respect, Tiret et al. (39)
suggested that the C allele of the A1166C polymorphism of
the angiotensin II type 1 receptor gene was associated with
a modified response of the receptor to angiotensin II,
modulating the relative risk conferred by the ACE D allele.
Others have not confirmed this interaction, partly attributed
to sample size or ethnicity (40).
Conclusions. Our data provide evidence of a two-fold
increased risk for CHD in subjects with the AGT-235T
genotype, while AGT-M235 is associated with a reduction
in risk, independently of BP. Whether AGT (M235T)
polymorphism mediates CHD related effects or acts as a
marker of other gene polymorphisms as AGT A(-6)G
needs further evaluation.
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